acute lymphoblastic leukemia
Conditions
Interventions
In CD19-positive non-Ph ALL, blinatumomab (Blina) will be used upfront to achieve and maintain MRD negativity. In CD19-negative non-Ph ALL, patients who remain MRD-positive after the second consolidat
Sponsors
Koichi Akashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with acute lymphoblastic leukemia (ALL) according to the WHO classification (5th edition) with >=25% blasts in the bone marrow, or patients diagnosed with mixed phenotype acute leukemia (MPAL) according to the WHO classification (5th edition) with >=25% blasts in the bone marrow and receiving ALL-directed chemotherapy. 2.Newly diagnosed patients who have not received chemotherapy or radiotherapy. The use of hydroxyurea or leukapheresis for tumor burden control before the start of the prephase treatment is permitted. 3.Patients aged between 16 and 70 years at the time of diagnosis. 4.Patients with an ECOG Performance Status of 0 to 2. 5.Patients without severe organ dysfunction. Total bilirubin =<2.0 mg/dL, creatinine=<2.0 mg/dL. 6.Patients who have provided written informed consent after receiving an explanation of the study.
Exclusion criteria
Exclusion criteria: 1. Blast cell surface immunoglobulin-positive Burkitt leukemia. 2.Patients with active double cancer. 3.Patients with difficult-to-control infections. 4. Cases with severe mental disorders. 5. Pregnant cases. 6.Other cases judged inappropriate by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year/5-year overall survival rate, 5-year disease-free survival rate, 3-year/5-year complete remission rate, remission rate (CR, MRDneg), protocol completion rate, treatment-related death (TRM) rate, adverse event rate | — |
Countries
Japan, none
Contacts
Public ContactShima Takahiro
Kyushu University Hospital
Outcome results
None listed